Cambrex Expands Generic API Research and Development Capabilities at Milan, Italy Site
Jun. 12, 2018
EAST RUTHERFORD, N.J., June 12, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it will expand research and development capabilities at its site in Paullo, Milan, Italy. The investment will be in the construction of a new 150m² R&D laboratory and the recruitment of additional scientists to increase the number of generic APIs in the company’s development portfolio.
The new laboratory will include 14 fume hoods and will combine both chemistry and analytical development capabilities, with the installation of glass lined reactors, as well as analytical instruments including multiple high and ultra-performance liquid chromatography, and gas chromatography systems. It is estimated building work will be completed by the end of 2018, allowing installation and validation of the analytical instruments to take place in Q1 2019.
“The generic API industry is growing due to the continued expiry of product patents, which results in the constant flow of new generic entrants to the market,” commented Aldo Magnini, Managing Director, Cambrex Milan. “The new laboratory will increase the number of programs we can be active in at any one time, allowing us to expand our portfolio of generic products.”
Cambrex currently manufactures over 70 generic APIs which are produced to cGMP standards and the Milan site comprises seven production departments, supported by a pilot plant, kilo-scale plant and development and analytical laboratories.
About CambrexCambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and continuous processing. For more information, please visit www.cambrex.com.
Contact: Alex Maw Director, Marketing and Communications Tel: +44 7803 443 155 Email: firstname.lastname@example.org